Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:NAALADL2-DRD3

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: NAALADL2-DRD3
	FusionPDB ID: 57029
	FusionGDB2.0 ID: 57029
		Hgene	Tgene
	Gene symbol	NAALADL2	DRD3
	Gene ID	254827	1814
	Gene name	N-acetylated alpha-linked acidic dipeptidase like 2	dopamine receptor D3
	Synonyms	-	D3DR\|ETM1\|FET1
	Cytomap	3q26.31	3q13.31
	Type of gene	protein-coding	protein-coding
	Description	inactive N-acetylated-alpha-linked acidic dipeptidase-like protein 2N-acetylated alpha-linked acidic dipeptidase 2NAALADase L2glutamate carboxypeptidase II-type non-peptidase homologue	D(3) dopamine receptoressential tremor 1
	Modification date	20200313	20200315
	UniProtAcc	Q58DX5 Main function of 5'-partner protein: FUNCTION: May be catalytically inactive.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000454872, ENST00000473253,	ENST00000295881, ENST00000383673, ENST00000460779, ENST00000467632,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	28 X 19 X 9=4788	2 X 2 X 2=8
	# samples	29	2
	** MAII score	log2(29/4788*10)=-4.04529834692857 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(2/8*10)=1.32192809488736
Fusion gene context	PubMed: NAALADL2 [Title/Abstract] AND DRD3 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: NAALADL2 [Title/Abstract] AND DRD3 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	NAALADL2(175455187)-DRD3(113858543), # samples:1
Anticipated loss of major functional domain due to fusion event.	NAALADL2-DRD3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. NAALADL2-DRD3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Tgene	DRD3	GO:0002031	G protein-coupled receptor internalization	18424554
Tgene	DRD3	GO:0006874	cellular calcium ion homeostasis	7911712
Tgene	DRD3	GO:0007186	G protein-coupled receptor signaling pathway	7911712
Tgene	DRD3	GO:0007191	adenylate cyclase-activating dopamine receptor signaling pathway	18424554
Tgene	DRD3	GO:0007195	adenylate cyclase-inhibiting dopamine receptor signaling pathway	7907363\|8666994\|18424554
Tgene	DRD3	GO:0034776	response to histamine	16839358
Tgene	DRD3	GO:0050482	arachidonic acid secretion	8301582
Tgene	DRD3	GO:0050709	negative regulation of protein secretion	16839358

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr3:175455187/chr3:113858543)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across NAALADL2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across DRD3 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000454872	NAALADL2	chr3	175455187	-	ENST00000460779	DRD3	chr3	113858543	-	2859	2118	128	2794	888
ENST00000454872	NAALADL2	chr3	175455187	-	ENST00000467632	DRD3	chr3	113858543	-	2801	2118	128	2794	888
ENST00000454872	NAALADL2	chr3	175455187	-	ENST00000295881	DRD3	chr3	113858543	-	2702	2118	128	2695	855
ENST00000454872	NAALADL2	chr3	175455187	-	ENST00000383673	DRD3	chr3	113858543	-	2801	2118	128	2794	888

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000454872	ENST00000460779	NAALADL2	chr3	175455187	-	DRD3	chr3	113858543	-	0.00048244	0.99951756
ENST00000454872	ENST00000467632	NAALADL2	chr3	175455187	-	DRD3	chr3	113858543	-	0.000457363	0.9995427
ENST00000454872	ENST00000295881	NAALADL2	chr3	175455187	-	DRD3	chr3	113858543	-	0.000424124	0.9995759
ENST00000454872	ENST00000383673	NAALADL2	chr3	175455187	-	DRD3	chr3	113858543	-	0.000457363	0.9995427

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for NAALADL2-DRD3

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
NAALADL2	chr3	175455187	DRD3	chr3	113858543	2118	646	SGEVILQIANEPVLPFNALDIALEVQ

Top

Potential FusionNeoAntigen Information of NAALADL2-DRD3 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

NAALADL2-DRD3_175455187_113858543.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:02	IANEPVLPF	0.999	0.9173	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:25	IANEPVLPF	0.999	0.9068	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:01	IANEPVLPF	0.9984	0.8772	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:08	IANEPVLPF	0.9982	0.6462	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:01	IANEPVLPF	0.9973	0.8636	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:03	IANEPVLPF	0.9964	0.7175	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B45:01	NEPVLPFNA	0.9954	0.6514	9	18
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:17	IANEPVLPF	0.9939	0.8287	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:18	IANEPVLPF	0.9926	0.6437	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:16	IANEPVLPF	0.9918	0.5338	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B48:01	LQIANEPVL	0.9863	0.6976	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:03	IANEPVLPF	0.9835	0.8326	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:03	EPVLPFNAL	0.9799	0.8096	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:01	EPVLPFNAL	0.9785	0.7749	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:08	EPVLPFNAL	0.978	0.6348	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B57:03	IANEPVLPF	0.9692	0.9303	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B58:01	IANEPVLPF	0.9685	0.789	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B58:02	IANEPVLPF	0.9514	0.8324	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B39:01	LQIANEPVL	0.9252	0.9462	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:04	EPVLPFNAL	0.9171	0.8342	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:02	EPVLPFNAL	0.9171	0.8342	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B14:01	EPVLPFNAL	0.9107	0.6081	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B14:02	EPVLPFNAL	0.9107	0.6081	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:04	IANEPVLPF	0.9088	0.9143	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:02	IANEPVLPF	0.9088	0.9143	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B52:01	IANEPVLPF	0.8968	0.9263	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B39:13	LQIANEPVL	0.8539	0.951	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:10	LQIANEPVL	0.7961	0.592	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B13:02	LQIANEPVL	0.7735	0.8295	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B13:01	LQIANEPVL	0.7711	0.9825	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:03	LQIANEPVL	0.7693	0.8385	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B39:01	EPVLPFNAL	0.7589	0.9073	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-A32:13	IANEPVLPF	0.6913	0.9458	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B08:01	EPVLPFNAL	0.5811	0.6677	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:37	LQIANEPVL	0.5613	0.616	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B08:09	EPVLPFNAL	0.5058	0.5947	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B52:01	LQIANEPVL	0.0898	0.9844	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:03	NEPVLPFNAL	0.8522	0.8122	9	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:04	NEPVLPFNAL	0.769	0.814	9	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:02	NEPVLPFNAL	0.769	0.814	9	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:01	LQIANEPVLPF	1	0.8595	5	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:21	IANEPVLPF	0.9989	0.8869	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:07	IANEPVLPF	0.9983	0.6273	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C03:08	IANEPVLPF	0.9979	0.8797	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C03:19	IANEPVLPF	0.9978	0.9876	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:05	IANEPVLPF	0.9972	0.8315	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:31	IANEPVLPF	0.9971	0.8468	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C15:04	IANEPVLPF	0.9929	0.8875	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C03:07	IANEPVLPF	0.9894	0.9759	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C12:12	IANEPVLPF	0.9819	0.9404	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C15:06	IANEPVLPF	0.9729	0.9175	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:04	LQIANEPVL	0.9663	0.9156	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C04:06	IANEPVLPF	0.9477	0.8238	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C12:04	IANEPVLPF	0.9389	0.9957	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B39:09	LQIANEPVL	0.9381	0.833	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C05:09	IANEPVLPF	0.9354	0.9075	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C03:14	IANEPVLPF	0.9331	0.972	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C06:03	IANEPVLPF	0.9325	0.995	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C07:95	IANEPVLPF	0.9277	0.6071	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B48:03	LQIANEPVL	0.9259	0.5286	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C07:19	IANEPVLPF	0.9183	0.6262	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:12	EPVLPFNAL	0.9171	0.8342	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:12	IANEPVLPF	0.9088	0.9143	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C08:04	IANEPVLPF	0.8948	0.9644	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C08:13	IANEPVLPF	0.8948	0.9644	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B51:07	IANEPVLPF	0.885	0.8246	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C04:14	IANEPVLPF	0.8844	0.6576	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B39:08	LQIANEPVL	0.8789	0.9193	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B14:03	EPVLPFNAL	0.8556	0.74	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B39:05	LQIANEPVL	0.8096	0.9411	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B39:10	EPVLPFNAL	0.7894	0.9024	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B39:09	EPVLPFNAL	0.7884	0.5985	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B42:02	EPVLPFNAL	0.7759	0.6853	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C02:06	IANEPVLPF	0.7111	0.9603	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B42:01	EPVLPFNAL	0.7108	0.6758	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C08:15	IANEPVLPF	0.698	0.9437	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C08:03	IANEPVLPF	0.6579	0.9821	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:05	LQIANEPVL	0.4703	0.9058	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C01:30	VLPFNALDI	0.0907	0.947	12	21
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C01:17	VLPFNALDI	0.0383	0.9248	12	21
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B39:10	NEPVLPFNAL	0.8907	0.8397	9	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:12	NEPVLPFNAL	0.769	0.814	9	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:05	LQIANEPVLPF	0.9903	0.8792	5	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B42:02	ANEPVLPFNAL	0.9089	0.5033	8	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C03:02	IANEPVLPF	0.9991	0.9636	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:11	IANEPVLPF	0.9989	0.8836	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C03:03	IANEPVLPF	0.9988	0.9851	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C03:04	IANEPVLPF	0.9988	0.9851	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:39	IANEPVLPF	0.9988	0.8037	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:11	IANEPVLPF	0.9986	0.8249	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C03:67	IANEPVLPF	0.9986	0.9693	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:27	IANEPVLPF	0.9985	0.8904	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:08	IANEPVLPF	0.9985	0.824	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:135	IANEPVLPF	0.9985	0.862	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:34	IANEPVLPF	0.9984	0.8772	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:125	IANEPVLPF	0.9984	0.8772	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:33	IANEPVLPF	0.9984	0.8772	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:43	IANEPVLPF	0.9984	0.8246	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:35	IANEPVLPF	0.9979	0.8596	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:24	IANEPVLPF	0.9978	0.8628	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:20	IANEPVLPF	0.9974	0.8806	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:77	IANEPVLPF	0.9973	0.8636	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:50	IANEPVLPF	0.9972	0.9283	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:23	IANEPVLPF	0.9971	0.8331	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:28	IANEPVLPF	0.997	0.8835	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:17	IANEPVLPF	0.9967	0.7135	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:30	IANEPVLPF	0.9967	0.7135	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:20	IANEPVLPF	0.9966	0.89	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:13	IANEPVLPF	0.9965	0.5345	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C03:17	IANEPVLPF	0.9958	0.9523	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:24	IANEPVLPF	0.9949	0.926	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C03:05	IANEPVLPF	0.9948	0.9134	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C12:02	IANEPVLPF	0.994	0.9709	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C16:04	IANEPVLPF	0.9933	0.9865	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C15:09	IANEPVLPF	0.9929	0.8875	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:12	IANEPVLPF	0.9883	0.8309	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C12:03	IANEPVLPF	0.9876	0.9843	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:13	IANEPVLPF	0.9835	0.8389	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B58:06	IANEPVLPF	0.9832	0.6848	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:23	EPVLPFNAL	0.9792	0.7327	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:73	LQIANEPVL	0.9791	0.9559	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:77	EPVLPFNAL	0.9785	0.7749	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:13	EPVLPFNAL	0.9754	0.8216	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:53	LQIANEPVL	0.9667	0.8863	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C16:01	IANEPVLPF	0.9651	0.9615	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C03:06	IANEPVLPF	0.9634	0.9847	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C15:05	IANEPVLPF	0.9619	0.9368	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C07:17	IANEPVLPF	0.9614	0.9581	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C15:02	IANEPVLPF	0.9583	0.8994	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:30	LQIANEPVL	0.9435	0.9561	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C04:03	IANEPVLPF	0.9401	0.7054	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:30	IANEPVLPF	0.9392	0.8881	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B39:02	LQIANEPVL	0.938	0.9508	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C05:01	IANEPVLPF	0.9354	0.9075	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B57:02	IANEPVLPF	0.9353	0.6534	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C04:04	IANEPVLPF	0.9326	0.8029	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:11	EPVLPFNAL	0.9267	0.8235	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B40:12	LQIANEPVL	0.9259	0.5286	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:09	EPVLPFNAL	0.9171	0.8342	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:24	EPVLPFNAL	0.9129	0.8414	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:09	IANEPVLPF	0.9088	0.9143	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:54	LQIANEPVL	0.9045	0.8576	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:30	EPVLPFNAL	0.8993	0.5758	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:17	EPVLPFNAL	0.8993	0.5758	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C16:02	IANEPVLPF	0.8822	0.9798	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B07:13	IANEPVLPF	0.8816	0.6932	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-A32:01	IANEPVLPF	0.8803	0.9396	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C02:02	IANEPVLPF	0.8332	0.9767	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C02:10	IANEPVLPF	0.8332	0.9767	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B39:11	LQIANEPVL	0.8184	0.9021	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B67:01	EPVLPFNAL	0.8099	0.6864	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B40:21	LQIANEPVL	0.8057	0.7058	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B18:04	IANEPVLPF	0.7638	0.9262	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C08:02	IANEPVLPF	0.698	0.9437	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B48:02	LQIANEPVL	0.6939	0.926	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C08:01	IANEPVLPF	0.6579	0.9821	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:13	LQIANEPVL	0.6394	0.9251	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B08:18	EPVLPFNAL	0.5811	0.6677	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:09	LQIANEPVL	0.5629	0.9172	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B18:07	IANEPVLPF	0.5242	0.8737	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:20	LQIANEPVL	0.4663	0.9382	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:28	LQIANEPVL	0.4412	0.9417	5	14
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B08:12	EPVLPFNAL	0.439	0.7419	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C17:01	IANEPVLPF	0.3679	0.8208	7	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B18:07	EPVLPFNAL	0.0904	0.8466	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:43	EPVLPFNAL	0.0533	0.7275	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:08	EPVLPFNAL	0.0342	0.7234	10	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C01:02	VLPFNALDI	0.0245	0.9176	12	21
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-C01:03	VLPFNALDI	0.0143	0.9001	12	21
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B67:01	NEPVLPFNAL	0.9056	0.5779	9	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B35:09	NEPVLPFNAL	0.769	0.814	9	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:33	LQIANEPVLPF	1	0.8595	5	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:34	LQIANEPVLPF	1	0.8595	5	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:27	LQIANEPVLPF	1	0.8847	5	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:125	LQIANEPVLPF	1	0.8595	5	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B67:01	ANEPVLPFNAL	0.997	0.6411	8	19
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	HLA-B15:20	LQIANEPVLPF	0.9888	0.9318	5	16

Top

Potential FusionNeoAntigen Information of NAALADL2-DRD3 in HLA II

NAALADL2-DRD3_175455187_113858543.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-0478	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1221	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1410	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1410	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1439	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1439	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1501	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1501	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1501	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1501	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1503	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1503	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1503	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1503	EVILQIANEPVLPFN	2	17
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1504	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1504	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1504	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1504	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1505	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1505	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1505	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1505	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1506	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1506	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1506	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1506	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1507	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1507	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1507	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1507	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1509	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1509	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1509	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1509	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1510	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1510	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1511	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1512	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1512	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1512	IANEPVLPFNALDIA	7	22
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1512	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1512	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1513	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1513	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1513	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1513	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1516	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1516	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1516	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1516	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1518	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1518	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1518	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1518	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1518	IANEPVLPFNALDIA	7	22
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1520	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1520	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1520	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1520	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1521	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1521	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1521	IANEPVLPFNALDIA	7	22
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1521	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1521	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1522	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1522	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1522	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1522	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1523	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1523	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1523	EVILQIANEPVLPFN	2	17
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1523	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1524	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1524	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1524	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1524	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1525	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1525	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1525	EVILQIANEPVLPFN	2	17
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1527	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1527	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1528	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1528	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1528	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1528	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1528	IANEPVLPFNALDIA	7	22
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1529	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1529	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1529	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1530	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1532	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1532	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1532	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1532	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1533	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1533	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1533	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1533	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1534	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1534	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1535	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1535	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1535	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1535	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1535	IANEPVLPFNALDIA	7	22
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1536	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1536	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1536	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1536	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1537	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1537	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1537	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1537	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1537	IANEPVLPFNALDIA	7	22
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1540	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1540	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1540	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1540	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1541	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1541	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1541	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1541	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1542	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1542	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1542	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1542	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1543	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1543	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1543	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1543	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1545	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1545	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1545	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1545	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1546	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1546	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1546	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1546	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1548	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1548	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1548	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1548	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1549	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1549	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1549	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1549	ANEPVLPFNALDIAL	8	23
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1549	IANEPVLPFNALDIA	7	22
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1605	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1605	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1607	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1607	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1614	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1614	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1615	SGEVILQIANEPVLP	0	15
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB1-1615	GEVILQIANEPVLPF	1	16
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB5-0202	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB5-0204	NEPVLPFNALDIALE	9	24
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2118	DRB5-0205	NEPVLPFNALDIALE	9	24

Top

Fusion breakpoint peptide structures of NAALADL2-DRD3

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
7313	QIANEPVLPFNALD	NAALADL2	DRD3	chr3	175455187	chr3	113858543	2118

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of NAALADL2-DRD3

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	7313	QIANEPVLPFNALD	-7.15543	-7.26883
HLA-B14:02	3BVN	7313	QIANEPVLPFNALD	-4.77435	-5.80965
HLA-B52:01	3W39	7313	QIANEPVLPFNALD	-6.80875	-6.92215
HLA-B52:01	3W39	7313	QIANEPVLPFNALD	-4.20386	-5.23916
HLA-A11:01	4UQ2	7313	QIANEPVLPFNALD	-7.5194	-8.5547
HLA-A11:01	4UQ2	7313	QIANEPVLPFNALD	-6.9601	-7.0735
HLA-A24:02	5HGA	7313	QIANEPVLPFNALD	-7.52403	-7.63743
HLA-A24:02	5HGA	7313	QIANEPVLPFNALD	-5.82433	-6.85963
HLA-B27:05	6PYJ	7313	QIANEPVLPFNALD	-3.28285	-4.31815
HLA-B44:05	3DX8	7313	QIANEPVLPFNALD	-5.91172	-6.94702
HLA-B44:05	3DX8	7313	QIANEPVLPFNALD	-4.24346	-4.35686

Top

Vaccine Design for the FusionNeoAntigens of NAALADL2-DRD3

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
NAALADL2-DRD3	chr3	175455187	chr3	113858543	10	19	EPVLPFNAL	ACCTTAAAGGGGACCCCACTGTCTGCT
NAALADL2-DRD3	chr3	175455187	chr3	113858543	12	21	VLPFNALDI	AAGGGGACCCCACTGTCTGCTCCATCT
NAALADL2-DRD3	chr3	175455187	chr3	113858543	5	14	LQIANEPVL	TAGAAGTTCAAAACAACCTTAAAGGGG
NAALADL2-DRD3	chr3	175455187	chr3	113858543	5	16	LQIANEPVLPF	TAGAAGTTCAAAACAACCTTAAAGGGGACCCCA
NAALADL2-DRD3	chr3	175455187	chr3	113858543	7	16	IANEPVLPF	TTCAAAACAACCTTAAAGGGGACCCCA
NAALADL2-DRD3	chr3	175455187	chr3	113858543	8	19	ANEPVLPFNAL	AAAACAACCTTAAAGGGGACCCCACTGTCTGCT
NAALADL2-DRD3	chr3	175455187	chr3	113858543	9	18	NEPVLPFNA	ACAACCTTAAAGGGGACCCCACTGTCT
NAALADL2-DRD3	chr3	175455187	chr3	113858543	9	19	NEPVLPFNAL	ACAACCTTAAAGGGGACCCCACTGTCTGCT

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
NAALADL2-DRD3	chr3	175455187	chr3	113858543	0	15	SGEVILQIANEPVLP	CACTTGATATAGCTTTAGAAGTTCAAAACAACCTTAAAGGGGACC
NAALADL2-DRD3	chr3	175455187	chr3	113858543	1	16	GEVILQIANEPVLPF	TTGATATAGCTTTAGAAGTTCAAAACAACCTTAAAGGGGACCCCA
NAALADL2-DRD3	chr3	175455187	chr3	113858543	2	17	EVILQIANEPVLPFN	ATATAGCTTTAGAAGTTCAAAACAACCTTAAAGGGGACCCCACTG
NAALADL2-DRD3	chr3	175455187	chr3	113858543	7	22	IANEPVLPFNALDIA	TTCAAAACAACCTTAAAGGGGACCCCACTGTCTGCTCCATCTCCA
NAALADL2-DRD3	chr3	175455187	chr3	113858543	8	23	ANEPVLPFNALDIAL	AAAACAACCTTAAAGGGGACCCCACTGTCTGCTCCATCTCCAACC
NAALADL2-DRD3	chr3	175455187	chr3	113858543	9	24	NEPVLPFNALDIALE	ACAACCTTAAAGGGGACCCCACTGTCTGCTCCATCTCCAACCCTG

Top

Information of the samples that have these potential fusion neoantigens of NAALADL2-DRD3

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
HNSC	NAALADL2-DRD3	chr3	175455187	ENST00000454872	chr3	113858543	ENST00000295881	TCGA-BB-4223-01A

Top

Potential target of CAR-T therapy development for NAALADL2-DRD3

Predicted 3D structure. We used RoseTTAFold.

295_NAALADL2-DRD3_t000_.e2e.pdb

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

NAALADL2

chr3:175455187

chr3:113858543

ENST00000454872

122_142

663

796.0

Transmembrane

Helical%3B Signal-anchor for type II membrane protein

Tgene

DRD3

chr3:175455187

chr3:113858543

ENST00000383673

188_209

401.0

Transmembrane

Helical%3B Name%3D5

Tgene

DRD3

chr3:175455187

chr3:113858543

ENST00000383673

330_351

401.0

Transmembrane

Helical%3B Name%3D6

Tgene

DRD3

chr3:175455187

chr3:113858543

ENST00000383673

367_386

401.0

Transmembrane

Helical%3B Name%3D7

Tgene

DRD3

chr3:175455187

chr3:113858543

ENST00000460779

188_209

401.0

Transmembrane

Helical%3B Name%3D5

Tgene

DRD3

chr3:175455187

chr3:113858543

ENST00000460779

330_351

401.0

Transmembrane

Helical%3B Name%3D6

Tgene

DRD3

chr3:175455187

chr3:113858543

ENST00000460779

367_386

401.0

Transmembrane

Helical%3B Name%3D7

Tgene

DRD3

chr3:175455187

chr3:113858543

ENST00000467632

188_209

401.0

Transmembrane

Helical%3B Name%3D5

Tgene

DRD3

chr3:175455187

chr3:113858543

ENST00000467632

330_351

401.0

Transmembrane

Helical%3B Name%3D6

Tgene

DRD3

chr3:175455187

chr3:113858543

ENST00000467632

367_386

401.0

Transmembrane

Helical%3B Name%3D7

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene	Hchr	Hbp	Henst	Tgene	Tchr	Tbp	Tenst	DeepLoc result
NAALADL2	chr3	175455187	ENST00000454872	DRD3	chr3	113858543	ENST00000295881
NAALADL2	chr3	175455187	ENST00000454872	DRD3	chr3	113858543	ENST00000383673

Top

Related Drugs to NAALADL2-DRD3

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to NAALADL2-DRD3

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)